Latest Acute myeloid leukemia Stories
Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising.
SAN DIEGO, April 22, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune
RIDGEFIELD, Conn., April 17, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S.
Transparency Market Research Report Added "Blood Disease Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database.
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.
SAN DIEGO, April 8, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune
New Pre-Clinical Data Presented at AACR Annual Meeting in San Diego SAN DIEGO, April 7, 2014 /PRNewswire/ -- MEI Pharma, Inc.
Phase I Demonstrates Quizartinib Tolerability in Combination with Chemotherapy SAN DIEGO, April 7, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company
Poor Efficacy and Physicians' Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group BURLINGTON,
Nearly half of patients with the most common form of adult leukemia are said to have normal chromosomes but appear instead to have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.
- A poem in which the author retracts something said in an earlier poem.